NASDAQ:FREQ Frequency Therapeutics (FREQ) Stock Price, News & Analysis Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$0.28▼$0.3250-Day Range$0.22▼$14.9852-Week Range$0.18▼$16.00Volume309,164 shsAverage Volume822,537 shsMarket Capitalization$10.94 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Frequency Therapeutics alerts: Email Address Ad Paradigm PressMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… A predicted Trump would win. You won’t believe what he’s predicting now.Click here to see it because it’s a SHOCKER… About Frequency Therapeutics Stock (NASDAQ:FREQ)Frequency Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics to activate a person's innate regenerative potential to restore function. Its Progenitor Cell Activation approach uses small molecules to activate progenitor cells within the body to create functional tissue. The company's lead product candidate is FX-322, which is in Phase IIb clinical trial to treat the underlying cause of sensorineural hearing loss. It is also developing medicines for patients across a range of degenerative conditions, including multiple sclerosis, and diseases of the muscle, gastrointestinal tract, skin, and bone. The company has a license and collaboration agreement with Astellas Pharma Inc. for the development and commercialization of FX-322, as well as collaboration and licensing agreements with Massachusetts Eye and Ear, the Massachusetts Institute of Technology, and The Scripps Research Institute. Frequency Therapeutics, Inc. was incorporated in 2014 and is headquartered in Lexington, Massachusetts.Read More Ad Paradigm PressMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… A predicted Trump would win. You won’t believe what he’s predicting now.Click here to see it because it’s a SHOCKER… FREQ Stock News HeadlinesMay 29, 2024 | msn.comHow to know when it's time to quit therapyMay 29, 2024 | msn.comNeed some rejuvenation? Hard to beat Wind Therapy on a Barnegat Bay sailboatJuly 6, 2024 | Crypto 101 Media (Ad)Top Hedge Funds Reveal A.I. Moonshot CoinsThe manager of top crypto hedge fund Pantera recently said every crypto company will soon be an artificial intelligence venture… And there are a handful of little-known crypto projects in the A.I. sector that they expect to benefit the most during this wave. May 29, 2024 | msn.comReducing cancer treatment frequency could cut greenhouse gas emissionsMay 28, 2024 | finanznachrichten.deIRLAB Therapeutics: IRLAB Presents at Redeye Growth Day 30 MayMay 27, 2024 | finanznachrichten.deIRLAB Therapeutics: IRLAB Appoints Kristina Torfgård as New CEOMay 24, 2024 | msn.comEverything You've Ever Wanted to Know (But Were Scared to Ask) About Menopausal Hormone TherapyMay 23, 2024 | finanznachrichten.deIRLAB Therapeutics: IRLAB Strengthens its Liquidity by Drawing SEK 25 million on a Previously Secured Loan FacilityJuly 6, 2024 | Crypto 101 Media (Ad)Top Hedge Funds Reveal A.I. Moonshot CoinsThe manager of top crypto hedge fund Pantera recently said every crypto company will soon be an artificial intelligence venture… And there are a handful of little-known crypto projects in the A.I. sector that they expect to benefit the most during this wave. May 23, 2024 | msn.comLemon verbena extract boosts sleep qualityMay 21, 2024 | msn.comUnlocking the Potential: Exploring Exosomes and Stem Cell Therapy for Home UseMay 20, 2024 | finance.yahoo.comNature Medicine Highlights Significant Improvement in Hand and Arm Function After Spinal Cord Injury with Use of ONWARD® ARC-EX® TherapyMay 17, 2024 | msn.comThe Best Red Light Therapy Devices for Wrinkles, Acne, and Fine LinesMay 17, 2024 | msn.comDoes Red Light Therapy Stimulate Collagen?May 17, 2024 | finance.yahoo.comBayer’s non-hormonal therapy reduces hot flashes in Phase III trialsMay 16, 2024 | msn.comCognitive behavioral therapy might improve sleep quality in teens suffering from anxietyMay 16, 2024 | markets.businessinsider.comBuy Rating for Ovid Therapeutics Based on Promising Drug Trials and Strategic PartnershipsMay 11, 2024 | msn.comWhat is Vitamin IV therapy and how does it work?See More Headlines Receive FREQ Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Frequency Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/15/2021Today7/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:FREQ CUSIPN/A CIK1703647 Webwww.frequencytx.com Phone781-315-4600FaxN/AEmployees46Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.89) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-81,580,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-107.67% Return on Assets-61.40% Debt Debt-to-Equity RatioN/A Current Ratio5.81 Quick Ratio5.81 Sales & Book Value Annual Sales$14.07 million Price / Sales0.78 Cash FlowN/A Price / Cash FlowN/A Book Value$1.96 per share Price / Book0.15Miscellaneous Outstanding Shares36,520,000Free Float30,385,000Market Cap$10.94 million OptionableNot Optionable Beta0.84 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesMr. David L. Lucchino (Age 53)Co-Founder, President, CEO & Director Comp: $1.02MMr. Richard J. Mitrano (Age 52)Vice President of Finance & Operations Mr. James P. AbelyAssociate General Counsel & SecretaryDr. John L. LaMattina Ph.D. (Age 73)Senior Advisor & Member of PCA Regenerative Medicine Advisory Board Key CompetitorsLeap TherapeuticsNASDAQ:LPTXCalciMedicaNASDAQ:CALCCleneNASDAQ:CLNNBioLineRxNASDAQ:BLRXDURECTNASDAQ:DRRXView All CompetitorsInsidersDavid L LucchinoSold 2,865 sharesTotal: $1,719.00 ($0.60/share)Richard J MitranoSold 227 sharesTotal: $143.01 ($0.63/share)David L LucchinoSold 2,895 sharesTotal: $1,881.75 ($0.65/share)Richard J MitranoSold 234 sharesTotal: $156.78 ($0.67/share)David L LucchinoSold 2,881 sharesTotal: $1,815.03 ($0.63/share) FREQ Stock Analysis - Frequently Asked Questions How were Frequency Therapeutics' earnings last quarter? Frequency Therapeutics, Inc. (NASDAQ:FREQ) announced its quarterly earnings data on Monday, November, 15th. The company reported ($0.73) EPS for the quarter, missing analysts' consensus estimates of ($0.57) by $0.16. When did Frequency Therapeutics IPO? Frequency Therapeutics (FREQ) raised $102 million in an initial public offering (IPO) on Thursday, October 3rd 2019. The company issued 6,700,000 shares at $14.50-$16.00 per share. J.P. Morgan, Goldman Sachs and Cowen acted as the underwriters for the IPO and Mizuho Securities was co-manager. What other stocks do shareholders of Frequency Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Frequency Therapeutics investors own include AbbVie (ABBV), Fulcrum Therapeutics (FULC), Akero Therapeutics (AKRO), Advanced Micro Devices (AMD), Pfizer (PFE), Taiwan Semiconductor Manufacturing (TSM) and Atreca (BCEL). This page (NASDAQ:FREQ) was last updated on 7/6/2024 by MarketBeat.com Staff From Our PartnersWhy Conservative Americans Are Turning to Gold in 2024Welcome to the financial rollercoaster of 2024, where inflation is relentless, stock markets are inflated, and...All American Assets | SponsoredBiden to drop out; finish out his term?On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in...Paradigm Press | SponsoredNvidia’s Quiet $1 Trillion PivotNvidia recently added $277 billion in market cap … IN ONE DAY.Weiss Ratings | SponsoredSilver Expected for Extreme Price ActionOur newest Silver Investing Guide reveals how savvy investors are capitalizing on silver's continued rise – PL...Colonial Metals | Sponsored1k a day while computer does all work?What I discovered is now helping me take in more than 1k a day. It's like a "magic key" to passive income ...Digital Mavericks Media | SponsoredWill Biden Be Replaced?There are growing rumors of a possible Joe Biden replacement following his first debate against Donald Trump. ...Stansberry Research | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredExposed: 3 CENT Crypto to Explode June 24th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Frequency Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Frequency Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
